Stockscreener 앱 받기
110.33
0.42%
0.46
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Monopar Therapeutics Inc (MNPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monopar Therapeutics Inc (MNPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Monopar Therapeutics Inc (MNPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MNPR|Monopar Therapeutics Inc|Price:110.450|Chg%:+0.580 - TradingKey
Monopar Therapeutics Inc (MNPR) Cash Flow - TradingKey
BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup - TipRanks
MONOPAR THERAPEUTICS INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $125 FROM $105 - webull.com
Monopar Therapeutics Inc (MNPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why is Monopar Therapeutics stock down 7.6% today? - Traders Union
Monopar Therapeutics Inc. (MNPR) stock price, news, quote and history - Yahoo Finance UK
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $115 - Moomoo
H.C. Wainwright raises Monopar stock price target to $125 on NDA filing - Investing.com
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125 - Moomoo
MNPR Maintained by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus
Monopar Therapeutics (MNPR) Proxy Filing Summary - Quartr
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125 - TipRanks
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease - Moomoo
Monopar Begins Rolling FDA NDA Submission for ALXN1840 - TipRanks
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease - The Manila Times
ALXN1840 Could Be First U.S. Wilson Therapy With Novel Mechanism in Decades - Stock Titan
Can leadership appointments spark further gains for Monopar Therapeutics stock? - Traders Union
Monopar adds commercial leaders ahead of drug filing By Investing.com - Investing.com Nigeria
Monopar Therapeutics stock slips below $105.4 support as weak price closes pressure momentum - Traders Union
MNPR stock draws attention as Monopar Therapeutics advances pipeline and reports recent financing me - Ad-hoc-news.de
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team - The Manila Times
Monopar adds commercial leaders ahead of drug filing - Investing.com
Former KalVista chief joins Monopar board as Wilson drug prep expands - Stock Titan
MNPR stock trades quietly as Monopar Therapeutics advances cancer pipeline - Ad-hoc-news.de
Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy) - Seeking Alpha
Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com - Investing.com South Africa
Monopar Therapeutics stock trades near $98.20–$111.48 range as buyer strength dominates session - Traders Union
Will Monopar Therapeutics stock regain momentum as buyers support the ongoing rally? - Traders Union
MNPR Q1 2026 Earnings: EPS Beats Estimates Significantly Despite Revenue AbsenceROA Comparison - dars.gov.et
Price to sales forward of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics stock drops almost 4% after earnings beat followed by downgrade to 'sell' - Traders Union
MNPR Q1 2026 Earnings: EPS Beats Estimates by 46% as Pipeline AdvancesEarnings Acceleration Picks - dars.gov.et
(MNPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares - Stock Titan
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
Monopar Therapeutics shares gain about 9.5% after immediate support holds above $100.45 - Traders Union
What's behind Monopar Therapeutics's latest 11.6% stock surge? - Traders Union
Monopar Therapeutics (MNPR) Surges 8.98% as Buyers Test Key Resistance ZoneSign of Weakness - dars.gov.et
Form 144 Monopar Therapeutics Inc. For: 7 July By Investing.com - Investing.com Nigeria
[144] Monopar Therapeutics SEC Filing - Stock Titan
MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline. - ad-hoc-news.de
Enterprise value to EBIT forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR) - Seeking Alpha
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding - Stock Titan
Liquidity Mapping Around (MNPR) Price Events - Stock Traders Daily
Monopar Therapeutics price target raised to $117 from $104 at BTIG - TipRanks
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $117 - Moomoo
MNPR Q1 2026 Earnings: Significant EPS Beat Highlights Progress in Clinical PipelineDiluted EPS Report - dars.gov.et
Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
MNPR Maintained by BTIG -- Price Target Raised to $117 - GuruFocus
1.97%
0.83%
자본화:
|
볼륨(24시간):